Journal article
Genome-wide characterization of the routes to pluripotency
SMI Hussein, MC Puri, PD Tonge, M Benevento, AJ Corso, JL Clancy, R Mosbergen, M Li, DS Lee, N Cloonan, DLA Wood, J Munoz, R Middleton, O Korn, HR Patel, CA White, JY Shin, ME Gauthier, KAL Cao, JI Kim Show all
Nature | Published : 2014
DOI: 10.1038/nature14046
Abstract
Somatic cell reprogramming to a pluripotent state continues to challenge many of our assumptions about cellular specification, and despite major efforts, we lack a complete molecular characterization of the reprograming process. To address this gap in knowledge, we generated extensive transcriptomic, epigenomic and proteomic data sets describing the reprogramming routes leading from mouse embryonic fibroblasts to induced pluripotency. Through integrative analysis, we reveal that cells transition through distinct gene expression and epigenetic signatures and bifurcate towards reprogramming transgene-dependent and-independent stable pluripotent states. Early transcriptional events, driven by h..
View full abstractGrants
Awarded by Australian Research Council
Funding Acknowledgements
We thank M. Gertsenstein and M. Pereira for chimaera production, C. Monetti for cell culture, R. Cowling for DNA purification, and K. Harpal for chimaera embryo sectioning and staining. We acknowledge the intellectual contributions of P. P. L. Tam and R. P. Harvey. A.N. is Tier 1 Canada Research Chair in Stem Cells and Regeneration. This work was supported by grants awarded to A.N., I. M. R. and P.W.Z. from the Ontario Research Fund Global Leadership Round in Genomics and Life Sciences grants (GL2-01-028), to A.N. from the Canadian stem cell network (9/5254 (TR3)) and from the Canadian Institutes of Health Research (CIHR MOP102575). This work received support from the Korean Ministry of Knowledge Economy (grant 10037410 to J.-S.S.), from the SNUCM Research Fund (grant 0411-20100074 to J.-S.S.), and from Macrogen Inc. (grant MGR03-11 and MGR03-12). The Stemformatics resource is supported by an Australian Research Council special research grant to Stem Cells Australia (C.A.W. and S.M.G.). The analysis of the miRNA was supported by grants from the National Health and Medical Research Council of Australia (1024852 to J.L.C. and T.P.) and the Australian Research Council (DP1300101928 to T.P.). W.R. is a Cancer Institute of NSW Fellow and with J.E.J.R. receives support from the Cancer Council of NSW and National Health & Medical Research Council (571156 and 1061906). J.E.J.R. receives funding from Cure the Future & Tour de Cure. K.-A.L.C. is supported, in part, by the Wound Management Innovation CRC (established and supported under the Australian Government's Cooperative Research Centres Program). S.M.G. received support from the Australian Research Council (SR110001002). C.A.W. is a QLD Smart Futures Fellow. M.B., J.M. and A.J.R.H. are supported by the Netherlands Proteomics Centre, and by the European Community's Seventh Framework Programme (FP7/2007-2013) by the PRIME-XS project grant agreement number 262067. P.W.Z. is the Canada Research Chair in Stem Cell Bioengineering. S.M.I.H. received a fellowship from the McEwen Centre of Regenerative Medicine.